Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors

David A. Peura, MD
Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville

Correspondence: David A. Peura, MD, Professor and Associate Chief, Division of Gastroenterology and Hepatology, University of Virginia Health System, P.O. Box 800708, Charlottesville, VA 22908; e-mail: DAP8V@hscmail.mcc.virginia.edu

The author has indicated that he does not have an affiliation with or financial interest in a commercial organization that poses a potential conflict of interest with his article.

David A. Peura, MD
Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville

Correspondence: David A. Peura, MD, Professor and Associate Chief, Division of Gastroenterology and Hepatology, University of Virginia Health System, P.O. Box 800708, Charlottesville, VA 22908; e-mail: DAP8V@hscmail.mcc.virginia.edu

The author has indicated that he does not have an affiliation with or financial interest in a commercial organization that poses a potential conflict of interest with his article.

David A. Peura, MD
Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville

Correspondence: David A. Peura, MD, Professor and Associate Chief, Division of Gastroenterology and Hepatology, University of Virginia Health System, P.O. Box 800708, Charlottesville, VA 22908; e-mail: DAP8V@hscmail.mcc.virginia.edu

The author has indicated that he does not have an affiliation with or financial interest in a commercial organization that poses a potential conflict of interest with his article.